[
International Worm Meeting,
2007]
5-Fluorouracil (5-FU) is a widely used anti-cancer drug for treatment of stomach, pancreatic, breast, colorectal, head and neck cancers. 5-FU has been used more than 40 years but it is still a mainstay drug of colorectal cancer. The anti-cancer drugs of pyrimidine antagonists including 5-FU are inserted into DNA and RNA or inhibit DNA synthesis. Therefore, DNA damage is occurred, and cancer cells become arrested or enter the apoptotic pathway. One of the obstacles of chemotherapy is the anti-cancer drug resistance. To study the resistant mechanism of cancer cells, we used C. elegans as a model system. We treated 5-FU to C. elegans and observed germ-line cell death and larval growth inhibition. Then we searched and studied C. elegans homologues of two enzymes in the 5-FU metabolic pathway. They are dihydropyrimidine dehydrogenase (DPD) and thymidylate synthase (TS). DPD converts 5-FU to inactive molecule, and TS is a major target of 5-FU. Overexpression of DPD and TS gives C. elegans resistance against 5-FU. From this result, we did genetic screen to find out genes related to the 5-FU resistant mechanism. We selected 15 mutants from 72,000 F1 screening. Six mutants are revealed to have mutations in ZK783.2 ORF, and ZK783.2 is uridine phosphorylase homologue. Uridine phosphorylase is one of enzymes in the pyrimidine salvage pathway. Uridine phosphorylase is expressed in most cells from early embryo to late adult. We also tested homologous genes of this pathway whether they are related to 5-FU resistance or not. Using RNAi, we know that some genes are related to 5-FU resistance but others are not. Now we are doing in vitro and in vivo enzyme activity of wild and mutant type uridine phosphorylases, and rescue experiment with human uridine phosphorylase. In addition, we are also doing mapping and cloning of another 5-FU resistant mutant.